Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 571-580 of 2279 for

Edit search filters
  1. Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

    Rochester, MN

  2. Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorder

    Rochester, MN

  3. An Open Label Extension Study of BMS-911543 In Subjects With Myelofibrosis

    Rochester, MN

  4. A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies

    Rochester, MN, Scottsdale/Phoenix, AZ

  5. Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study to Evaluate the Safety and Effectiveness of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer

    Jacksonville, FL, Rochester, MN

  7. A Study to Evaluate Hepcidin Mimetic in Patients With Polycythemia Vera

    Scottsdale/Phoenix, AZ

  8. Study of Cabozantinib Combined With Atezolizumab Vs. Second Novel Hormonal Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer

    Rochester, MN

  9. A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

    Rochester, MN

  10. A Study to Compare Radiation Therapy + Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer

    Albert Lea, MN, Scottsdale/Phoenix, AZ, La Crosse, WI, Rochester, MN

.

Mayo Clinic Footer